

Fragment-based Drug Discovery at WuXi AppTec's HitS



Advantages of FBDD


High hit rates (3-10%)

Efficient sampling of chemical space

a diverse set of 1000 fragments represents its chemical space about as effectively as would 10 trillion diverse drug-sized molecules

Ideally suited for targeting PPIs


they can bind to small pockets available on the protein surface



Predictor of protein druggability


Obtaining high hit rates is an excellent predictor that high-affinity, small molecule ligands can be identified.

Low hit rates (< 0.1%) strongly suggest an undruggable pocket.



Often unique binding profiles

high-quality interactions between fragment and target



Chemical optimization

ability to optimize pharmacokinetics profile simultaneously with potency as fragment hit grows to clinical candidate.

WuXi Fragment Library

Diverse collection of about 3100 fragments

Key pharmacophores









Synthetically accessible

PAINS, REOS, SMART filter

Appropriate complexity


“Rule-of-three” compliant

Physicochemical properties of fragment library




TRIC, MST & SPR based FBDD Workflow (3100 fragments)


Protein – Fragment Screening – Hit Confirmation – Structure Generation – Fragment Growth




- Protein production
- Assay development



- Single-dose screen
- K_d determination (hit validation)



- Thermal shift (nanoDSF)
- Kinetics (e.g., SPR)
- Binding (e.g., MST)
- Thermodynamics (e.g. ITC)



- Crystallography
- NMR




- *In silico* fragment growth
- SAR by catalogue
- MedChem
- Fragment-to-IND development

Faster with high-speed fragment screening

From the fragment library to the list of hits within few hours



Dianthus NT.23PicoDuo
384 data points within 30 min




Case Study: STING

Biophysical toolbox for STING fragment screening


Screening

MST and TRIC




Hit Confirmation

Surface Plasmon Resonance (SPR)




Hit Confirmation

nanoDSF



X-ray
crystallography



STING study in numbers

2600
fragments

3
orthogonal assays


66
binders

10 – 500 μ M
affinity


66
in crystallization

Crystallography-based FBDD Workflow (few 10 - 100 fragments)

Protein – Library Selection – Soaking – Structure Generation – Fragment Growth




- Crystal Grade Protein production



- Library selection (any provider)



- Identification of crystallization conditions
- DMSO tolerance test
- Fragment soaking
- Data collection



- Automated data processing
- Auto-refinement pipeline and PanDAA
- Manual refinement of chosen hits




- *In silico* fragment growth
- SAR by catalogue
- MedChem
- Fragment-to-IND development

NMR-based Fragment Screening (1500 fragments)


Ligand vs. Protein based

Protein- based



- Usually 2D HSQC
- Requires isotope labeling
- Typically > 100 mg protein required
- Delivers SAR information
- Very low false positive/negative probability
- Easy to implement and interpret the data

Ligand-based



- Usually fast 1D experiments
- No labelling needed
- Typically 10 mg protein required
- Prone to false positives/negatives and unspecific binding
- More difficult implementation and data analysis

Crelux GmbH a WuXi AppTec company
Am Klopferspitz 19a
82152 Martinsried
Germany

Contact: HitS_service@wuxiapptec.com

www.crelux.com
www.wuxiapptec.com

